We have heard lots of news about sodium-glucose transporter type 2 (SGLT2) inhibitors over the last year or so. Canagliflozin being the first drug in this class has been highlighted in many of the studies. In one the two trials of the Canagliflozin Cardiovascular Assessment Study (CANVAS) program, a 56% increased fracture risk with canagliflozin was seen. The question that this study left was whether the increased fracture risk was limited to patients in study with high baseline risk.
However, an interesting recent systematic review of clinical trial data found no association between canagliflozin and increased fracture risk. It is worth noting that these patients with Type 2 diabetes were relatively young in this review. To read more about this systematic review, please click on link below.
Please share your thoughts and subscribe to receive my blogs.
#canagliflozin #fracture #risk
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.